CDC Expects 200k COVID-19 Deaths By October As Dreaded 'Second Wave' Arrives: Live Updates
COVID-19 is deadlier for black Brazilians, a legacy of structural racism that dates back to slavery
A drug for the treatment of COVID-19 complications is registered in Russia
Heart injury among hospitalized COVID-19 patients associated with higher risk of death
Big UK trial says hydroxychloroquine has no effect on COVID-19
Junshi Biosciences Kicks Off China’s First Covid-19 Antibody Trial
Intravacc Partners to Develop Intranasal COVID-19 Vaccine
Compare the flu pandemic of 1918 and COVID-19 with caution – the past is not a prediction
Estimating a US price tag of $5K per course, remdesivir is set to make billions for Gilead, says key analyst
Three charts that show where the coronavirus death rate is heading
Opening up US will trigger more COVID-19 cases, but disease models suggest how to avoid a second peak
Abiomed’s Heart Pump Gets FDA Emergency Use Status For Covid-19 Patients
3 "Strong Buy" Penny Stocks That Offer Massive Potential Gains
Tobacco use and coronavirus (COVID-19): A deadly but preventable association
Hutchins Roundup: Living standards, macroprudential policies, and more
Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery
WHO halts hydroxychloroquine trial in COVID-19 following safety concerns
Researchers define exactly what they saw in the first positive remdesivir study for Covid-19. But what's that worth to Gilead?
Some patients with bladder cancer ‘can’t wait’ for treatment during the COVID-19 pandemic
3 "Strong Buy" Biotech Stocks Under $5 With Massive Upside Potential
Fight COVID-19 Deaths With Personal Responsibility
Massif Capital: Long Position In Bakkafrost P/F (BAKKA)
COVID-19 much more fatal for men, especially taking age into account
Skilled partners in the conduct of HIV prevention trials join COVID-19 response
Coronavirus Shakes Markets—Likely Temporarily
COVID-19: Science and Economics
FDA issues two guidances to accelerate Covid-19 treatments
Merck CPO Julie Gerberding On The Deadliness Of Covid-19
Gilead’s Remdesivir Will Be Distributed By State Health Departments
NIH clinical trial tests Remdesivir plus anti-inflammatory drug Baricitinib for COVID-19